A 21 years follow-up of 7.8 years of intensified, multifactorial, target-driven treatment of type 2 diabetes (T2D) with microalbuminuria demonstrated a median of 7.9 years of gain of life and free from incident cardiovascular disease. The study included 160 Danish patients with T2D and microalbuminuria from 1993. The patients were randomly assigned to receive either conventional therapy or intensified, multifactorial treatment including both behavioral and pharmacological approaches. After 7.8 years the study continued as an observational follow-up with all patients receiving treatment as for the original intensive-therapy group. Thirty-eight intensive-therapy patients vs 55 conventional-therapy patients died during follow-up. The patients in the intensive-therapy group survived for a median of 7.9 years longer than the conventional-therapy group patients. Median time before first cardiovascular event after randomization was 8.1 years longer in the intensive-therapy group. The hazard for all microvascular complications was decreased in the intensive-therapy group except for peripheral neuropathy. The study suggests the importance of early, intensified multifactor control in patients with complicated T2D. Source: http://link.springer.com/
经21年的随访，一项对2型糖尿病并发微量蛋白尿7.8年的强化，多方面，靶向治疗显示寿命延长平均7.9年， 且无心血管病的发生。该研究自1993年起，共纳入160例丹麦2型糖尿病并发微量蛋白尿患者。患者随机分配接受常规治疗或强化，多因素治疗，包括行为和药物两方面。7.8年后，所有患者均接受原强化治疗组的治疗，继续观察随访。强化治疗组38名，常规治疗组55名患者随访期间死亡。强化治疗组患者的寿命比常规治疗组患者平均延长7.9年。随机分组后强化治疗组第一次心血管事件发生的平均时间延长了8.1年。强化治疗组所有微血管并发症风险均降低，末梢神经病变除外。该研究表明早期，加强多方面控制糖尿病的重要性。来源：http://link.springer.com/